Login / Signup

Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib.

Jorge E CortesDelphine ReaMichael J MauroDiana TranPearl WangKejal JadhavAurore YocollyKoji Sasaki
Published in: Journal of medical economics (2023)
In the ASCEMBL trial, asciminib-treated patients with CML-CP in 3L + maintained lower resource utilization compared to bosutinib over the long-term.
Keyphrases
  • chronic myeloid leukemia
  • healthcare
  • study protocol
  • clinical trial
  • phase iii
  • phase ii
  • randomized controlled trial
  • social media